SCHEMBL2646595

SCHEMBL2646595

O=C(C=Cc1ccccc1)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1B1 Q16678 10/20 0.66
MAOB P27338 6/20 0.66
MAPT P10636 3/20 0.66
TNFRSF1A P19438 2/20 0.66
MEN1 O00255 2/20 0.66
HSPD1 P10809 2/20 0.66
HSPE1 P61604 2/20 0.66
KMT2A Q03164 2/20 0.66
CYP1A1 P04798 2/20 0.66
ALDH1A1 P00352 1/20 0.66
BCHE P06276 2/20 0.62
PLIN1 O60240 1/20 0.62
LMNA P02545 1/20 0.62
ACHE P22303 1/20 0.62
RECQL P46063 1/20 0.62
PLIN5 Q00G26 1/20 0.62
ABHD5 Q8WTS1 1/20 0.62
MAOA P21397 2/20 0.61
CYP3A4 P08684 2/20 0.59
STS P08842 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664927 0.94 CYP3A4 (0.66) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL2646597 0.94 CYP3A4 (0.66) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL2647392 0.92 CYP2D6 (0.63) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL2647212 0.92 SRD5A2 (0.58) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL9071415 0.92 CYP2D6 (0.57) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL2646840 0.92 CYP2D6 (0.57) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL9071316 0.92 CYP2D6 (0.57) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL2647210 0.92 SRD5A2 (0.58) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL2646839 0.92 CYP2D6 (0.57) CYP1B1MAOBMAPTTNFRSF1AMEN1
SCHEMBL25202905 0.90 XDH (0.67) CYP1B1MAOBMAPTTNFRSF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114524829-B Preparation method of imidazo [2,1-b ] thiazole derivative 新疆大学 2024-04-02 CN disclosed
CN-114524829-A Preparation method of imidazo [2,1-b ] thiazole derivative 新疆大学 2022-05-24 CN disclosed
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR CYP1B1 3336/4885MAOB 3317/4885MAPT 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.